LONDON, UK: AstraZeneca has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec. AstraZeneca will make payment of $425 million, for which a provision has been taken. The agreements effectively resolve the product liability claims that are currently pending in the Multidistrict Litigation in the US District Court for the…
All posts tagged AstraZeneca
AstraZeneca setting up R&D centre in Cambridge, Massachusetts
LONDON: AstraZeneca has announced plans to open a new site at the heart of the Cambridge, MA, life sciences and innovation hub. It will be a strategic R&D centre for AstraZeneca, as well as Alexion’s new corporate headquarters. AstraZeneca is working with BXP (NYSE:BXP) on development of the new site. The site will bring together approximately 1,500 R&D, commercial…
AstraZeneca signs multi-billion dollar deal with Ionis Pharmaceuticals
LONDON, UK: AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-L. The companies will jointly develop and commercialise eplontersen in the US, while AstraZeneca will develop and commercialise it in the rest of the world, except in Latin America. Under the terms of the agreement, the upfront…
AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma
LONDON, UK: AstraZeneca has agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma). Both medicines are delivered via the Genuair device and used for the treatment of patients with chronic obstructive pulmonary disease (COPD). The agreement will ensure continued patient access to these established medicines. Covis…
AstraZeneca to fully acquire Caelum Biosciences
LONDON, UK: AstraZeneca‘s Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences for CAEL-101, a potentially first-in-class fibril-reactive monoclonal antibody (mAb) for the treatment of light chain (AL) amyloidosis. AL amyloidosis is a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and…
AstraZeneca plans $360 million Irish manufacturing investment
LONDON, UK: AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland to ensure the Company’s global supply network is fit for future growth, a bourse filing said. The new plant will allow for late-stage development and early commercial supply, adopting state of the art process…
AstraZeneca complete acquisition of Alexion Pharmaceuticals
LONDON, UK: AstraZeneca today completed the acquisition of Alexion Pharmaceuticals Inc. The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca. AstraZeneca now has an enhanced scientific presence in immunology and, through Alexion’s innovative complement-biology platform and robust pipeline, will continue to…
AstraZeneca appoints Aradhana Sarin as new Chief Financial Officer
LONDON, UK: AstraZeneca PLC has appointed Aradhana Sarin as an Executive Director and Chief Financial Officer, conditional upon closing of AstraZeneca’s acquisition of Alexion Pharmaceuticals Inc. Dr. Sarin is currently Executive Vice-President, Chief Financial Officer of Alexion. Further biographical details are set out below. Dr. Sarin will relocate from the US and be based in…
AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan
LONDON: AstraZeneca‘s COVID-19 vaccine, Vaxzevria, formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2. The Japanese Ministry of Health, Labour and Welfare granted the approval based on positive Phase III efficacy and safety data from…
AstraZeneca US vaccine trial met primary endpoint
LONDON: The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization, a news release said. This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had a 2:1…
AstraZeneca notifies non-executive board changes
LONDON: AstraZeneca PLC announced today that Non-Executive Directors Geneviève Berger and Graham Chipchase intend to retire from the Board at the conclusion of the Company’s Annual General Meeting on 30 April 2021. By that date, each will have served on the Board for nine years. All other Non-Executive Directors will present themselves for election or…
AstraZeneca agrees to divest Viela shareholding for upto $780mn
STOCKHOLM: AstraZeneca Plc has agreed, subject to certain limited exceptions, to divest its 26.7% ownership in Viela Bio Inc. as part of the proposed acquisition of Viela by Horizon Therapeutics plc, a news release said. AstraZeneca is anticipating to receive cash proceeds and profit of c.$760-$780 million upon closing for the sale of the holding,…